<DOC>
	<DOCNO>NCT02884635</DOCNO>
	<brief_summary>The objective study evaluate efficacy , pharmacokinetics , pharmacodynamics safety ASP1707 combination MTX postmenopausal female patient RA .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety ASP1707 Postmenopausal Female Patients With Rheumatoid Arthritis Taking Methotrexate</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Subject RA diagnose accord 1987 ACR criterion 2010 ACR/EULAR criterion . Subject meet ACR 1991 Revised Criteria Classification Global Functional Status RA Class I , II , III . subject active RA evidence following : ≥ 6 tender/painful joint ( use 68joint assessment ) ≥ 6 swollen joint ( use 66joint assessment ) CRP ( Creactive protein ) &gt; 0.3 mg/dL ESR ( Erythrocyte sedimentation rate ) &gt; 28 mm/hr screening . Subject continuously receive MTX able continue stable dose MTX . Subject receive follow drug , receive drug stable dosage : Nonsteroidal antiinflammatory drug , oral morphine equivalent opioid analgesic , acetaminophen , oral corticosteroid . Inadequate responder biologic DMARD ( Diseasemodifying antirheumatic drug ) . Subject take investigational research product prohibit within 12 week ( 84 day ) within 5 halflives , whichever longer , prior screen . Subject undergone surgery residual effect assess joint , schedule undergo surgery may affect study evaluation assess joint . Subject another type inflammatory arthritis RA . Subject meet follow criterion laboratory value screen : White blood cell count &lt; 4000/μL Platelet count &lt; 100000/μL ALT ( Alanine Aminotransferase ) ≥ 2 x ULN ( Upper Limit Normal ) AST ( Aspartate Aminotransferase ) ≥ 2 x ULN Total bilirubin ≥ 1.5 x ULN Positive Hepatitis B surface antigen , Hepatitis B virusDNA quantitation , Hepatitis C virus antibody Subject positive QuantiFERONTB Gold test Tspot . Subject history concurrent malignant tumor . Subject ongoing severe , progressive , uncontrolled renal , hepatic , hematological , gastrointestinal , metabolic , endocrine , pulmonary , cardiac , neurological , infectious , autoimmune disease except RA , diseases preclude subject 's participation study . Subject history clinically significant allergy . Subject clinically significant abnormality 12lead Electrocardiogram . Subject history positive Human Immunodeficiency Virus infection .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Methotrexate</keyword>
	<keyword>ASP1707</keyword>
	<keyword>Rheumatoid arthritis</keyword>
</DOC>